Polar Capital Holdings Plc Boosts Position in Insulet Corporation $PODD

Polar Capital Holdings Plc raised its position in Insulet Corporation (NASDAQ:PODD) by 150.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 148,299 shares of the medical instruments supplier’s stock after purchasing an additional 88,982 shares during the period. Polar Capital Holdings Plc’s holdings in Insulet were worth $42,153,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in PODD. Larson Financial Group LLC raised its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in Insulet in the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Insulet during the 4th quarter valued at about $28,000. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in Insulet by 68.8% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 55 shares in the last quarter. Finally, Fideuram Asset Management Ireland dac acquired a new position in Insulet during the fourth quarter worth about $41,000.

Insulet Stock Performance

NASDAQ:PODD opened at $147.69 on Wednesday. The firm has a 50 day simple moving average of $167.67 and a 200-day simple moving average of $229.40. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm has a market cap of $10.23 billion, a PE ratio of 34.35, a P/E/G ratio of 1.17 and a beta of 1.13. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts expect that Insulet Corporation will post 6.46 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Benchmark reiterated a “buy” rating on shares of Insulet in a research report on Wednesday, May 27th. Sanford C. Bernstein reduced their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Leerink Partners lowered their target price on Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Weiss Ratings downgraded Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Finally, Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $240.78.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.